Network


Latest external collaboration on country level. Dive into details by clicking on the dots.

Hotspot


Dive into the research topics where Tsuneo Oda is active.

Publication


Featured researches published by Tsuneo Oda.


Journal of Chromatography B: Biomedical Sciences and Applications | 1993

Automated high-performance liquid chromatographic determination of hydroxylysylpyridinoline and lysylpyridinoline in urine using a column-switching method

Yoshinobu Yoshimura; Koji Ohnishi; Misako Hamamura; Tsuneo Oda; Takashi Sohda

An on-line urine clean-up system was developed for the simultaneous determination of free and total pyridinoline, hydroxylysyl-pyridinoline (HP) and lysylpyridinoline (LP) by high-performance liquid chromatography (HPLC) using a column-switching technique. The method is based on a combination of gel permeation chromatography (GPC) and ion-pair reversed-phase HPLC. In the GPC column, pyridinoline is preseparated from endogenous urinary substances with 0.03 M heptafluorobutyric acid (HFBA) as the mobile phase. After column switching, the eluate fraction containing pyridinoline is further separated by ion-pair chromatography using an octadecylsilica (ODS) column with 0.03 M HFBA-acetonitrile (81:19) as the mobile phase. The detection limits were 36 and 44 pmol/ml for free and total HP, respectively, and 44 pmol/ml for both free and total LP at a signal-to-noise ratio of 3. The coefficients of variation for free and total pyridinoline were 1.5 and 3.5%, respectively. The determination of one sample including the clean-up is completed within 25 min. This system is precise and is useful for the determination of pyridinoline in large amounts of urine. The usefulness of pyridinoline as a biomedical marker for bone resorption was also examined.


Journal of Pharmaceutical and Biomedical Analysis | 2002

Highly sensitive liquid chromatography-tandem mass spectrometry method for quantification of a new bone anabolic agent, TAK-778, in human serum

Koichiro Teshima; Takahiro Kondo; Chie Maeda; Tsuneo Oda; Toshiaki Hagimoto; Ryoichi Tsukuda; Yoshinobu Yoshimura

A liquid chromatography-tandem mass spectrometric (LC-MS-MS) method for the highly sensitive determination of a new bone-anabolic agent, TAK-778 in human serum was developed. The internal standard (I.S.) used was deuterated TAK-778. TAK-778 and I.S. were extracted from serum samples with diethyl ether at neutral pH. A turbo ion spray interface was used as the ion source of LC-MS-MS, and the analysis was performed in the selected reaction monitoring mode. The lower limit of quantification was 0.02 ng/ml when 0.4 ml of serum was used, and the standard curve was linear in the range of 0.02-10 ng/ml. The method was precise; the intra- and inter-day precision of the method was not more than 17.9%. The accuracy of the method was good with the deviations between added and calculated concentration of TAK-778 being typically within 9.0%.


Bioorganic & Medicinal Chemistry | 2018

Discovery of orally efficacious RORγt inverse agonists. Part 2: Design, synthesis, and biological evaluation of novel tetrahydroisoquinoline derivatives

Mitsunori Kono; Tsuneo Oda; Michiko Tawada; Takashi Imada; Yoshihiro Banno; Naohiro Taya; Tetsuji Kawamoto; Hidekazu Tokuhara; Yoshihide Tomata; Naoki Ishii; Atsuko Ochida; Yoshiyuki Fukase; Tomoya Yukawa; Shoji Fukumoto; Hiroyuki Watanabe; Keiko Uga; Akira Shibata; Hideyuki Nakagawa; Mikio Shirasaki; Yasushi Fujitani; Masashi Yamasaki; Junya Shirai; Satoshi Yamamoto

A series of tetrahydroisoquinoline derivatives were designed, synthesized, and evaluated for their potential as novel orally efficacious retinoic acid receptor-related orphan receptor-gamma t (RORγt) inverse agonists for the treatment of Th17-driven autoimmune diseases. We carried out cyclization of the phenylglycinamide core by structure-based drug design and successfully identified a tetrahydroisoquinoline carboxylic acid derivative 14 with good biochemical binding and cellular reporter activity. Interestingly, the combination of a carboxylic acid tether and a central fused bicyclic ring was crucial for optimizing PK properties, and the compound 14 showed significantly improved PK profile. Successive optimization of the carboxylate tether led to the discovery of compound 15 with increased inverse agonistic activity and an excellent PK profile. Oral treatment of mice with compound 15 robustly and dose-dependently inhibited IL-17A production in an IL23-induced gene expression assay.


Journal of Pharmacology and Experimental Therapeutics | 1999

Enhancement of Osteogenesis In Vitro and In Vivo by a Novel Osteoblast Differentiation Promoting Compound, TAK-778

Kohei Notoya; Hirofumi Nagai; Tsuneo Oda; Masayuki Gotoh; Tetsuo Hoshino; Hiroya Muranishi; Shigehisa Taketomi; Takashi Sohda; Haruhiko Makino


Archive | 1998

Anilide derivative, production and use thereof

Mitsuru Shiraishi; Takahito Kitayoshi; Yoshio Aramaki; Susumu Honda; Tsuneo Oda


Journal of Medicinal Chemistry | 1999

Synthesis of novel 2-benzothiopyran and 3-benzothiepin derivatives and their stimulatory effect on bone formation.

Tsuneo Oda; Kohei Notoya; Masayuki Gotoh; Shigehisa Taketomi; Yukio Fujisawa; Haruhiko Makino; Takashi Sohda


Chemical & Pharmaceutical Bulletin | 2004

Synthesis of 1-benzothiepine and 1-benzazepine derivatives as orally active CCR5 antagonists.

Yoshio Aramaki; Masaki Seto; Tomohiro Okawa; Tsuneo Oda; Naoyuki Kanzaki; Mitsuru Shiraishi


Archive | 1995

Phosphonic acid compounds, their production and use

Takashi Sohda; Shigehisa Taketomi; Tsuneo Oda


Archive | 2002

Bicyclic derivative, its production and use

Tsuneo Oda; Takashi Imada; Kenichiro Naito; Toshiya Tamura; Shuichi Furuya


Archive | 2002

Bicyclic derivative, process for producing the same, and use

Tsuneo Oda; Takashi Imada; Kenichiro Naito; Toshiya Tamura; Shuichi Furuya

Collaboration


Dive into the Tsuneo Oda's collaboration.

Top Co-Authors

Avatar

Shigehisa Taketomi

Takeda Pharmaceutical Company

View shared research outputs
Top Co-Authors

Avatar

Takashi Sohda

Takeda Pharmaceutical Company

View shared research outputs
Top Co-Authors

Avatar

Hidekazu Tokuhara

Takeda Pharmaceutical Company

View shared research outputs
Top Co-Authors

Avatar

Naohiro Taya

Takeda Pharmaceutical Company

View shared research outputs
Top Co-Authors

Avatar

Takashi Imada

Takeda Pharmaceutical Company

View shared research outputs
Top Co-Authors

Avatar

Yoshiyuki Fukase

Takeda Pharmaceutical Company

View shared research outputs
Top Co-Authors

Avatar

Mitsuru Shiraishi

Takeda Pharmaceutical Company

View shared research outputs
Top Co-Authors

Avatar

Naoyuki Kanzaki

Takeda Pharmaceutical Company

View shared research outputs
Top Co-Authors

Avatar

Yoshio Aramaki

Takeda Pharmaceutical Company

View shared research outputs
Top Co-Authors

Avatar

Kouichi Iwanaga

Takeda Pharmaceutical Company

View shared research outputs
Researchain Logo
Decentralizing Knowledge